iSERA Lifesciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakhs)
iSERA Lifesciences Ltd · Outcome · 04 Nov 2026, 11:06 pm
iSERA Lifesciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakhs) ■ Revenue: 0.0 ■ EBITDA: -20.3 (-6656.7% YoY | +39.7% QoQ) ■ EBITDA Margin (%): 0.0 ■ PAT: -13.1 (Profit to Loss YoY | +61.0% QoQ) ■ EPS (INR): -0.62 (Profit to Loss YoY | +61.3% QoQ)
Original exchange filing (PDF)
More announcements from iSERA Lifesciences Ltd
- Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Administrative Warning Letter received .... · 15 Nov 2026
- Dissemination of Warning Letter of SEBI · 12 Nov 2026
- We hereby submit the revised un-Audited Financial result for Half year ended September 2026 under regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 · 05 Nov 2026
- We hereby submit that pursuant to Regulation 15(2) of SEBI (LODR) Regulations, 2015, the compliance with the corporate governance provisions as specified in Regulations 17, 18, 19, 20, .... · 04 Nov 2026
- We hereby submit the Un-Audited Financial Result for the quarter and half yearly ended September 2026 · 04 Nov 2026
- Isera Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve the Un-Audited Financial .... · 04 Nov 2026
- Disclosure under Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 - Continual Disclosure consequent to Preferential Allotment of .... · 09 Oct 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Archana Lonkar · 07 Oct 2026
